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ABBREVIATIONS 
Polyglutamine (PolyQ), Huntingtin (Htt), Htt Exon 1 (Httex1), Huntington’s Disease (HD), Pulse Shape 
Analysis (PulSA), Cells With Inclusions (i), Cells With Diffuse Httex1 (ni), Relative Fluorescence Units 
(RFU), Ingenuity Pathway Analysis (IPA), False Discovery Rate (FDR), Wild-Type (WT), Green 
Fluorescent Protein (GFP), Region Of Interest (ROI). 
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ABSTRACT 
Huntington’s disease is caused by polyglutamine (polyQ)-expansion mutations in the CAG tandem 
repeat of the Huntingtin gene. The central feature of Huntington’s disease pathology is the 
aggregation of mutant Huntingtin (Htt) protein into micrometer-sized inclusion bodies.  Soluble mutant 
Htt states are most proteotoxic and trigger an enhanced risk of death whereas inclusions confer 
different changes to cellular health, and may even provide adaptive responses to stress. Yet the 
molecular mechanisms underpinning these changes remain unclear.  Using the flow cytometry 
method of pulse-shape analysis (PulSA) to sort neuroblastoma (Neuro2a) cells enriched with mutant 
or wild-type Htt into different aggregation states, we clarified which transcriptional signatures were 
specifically attributable to cells before versus after inclusion assembly. Dampened CREB signalling 
was the most striking change overall and invoked specifically by soluble mutant Httex1 states.  
Toxicity could be rescued by stimulation of CREB signalling.  Other biological processes mapped to 
different changes before and after aggregation included NF-kB signalling, autophagy, SUMOylation, 
transcription regulation by histone deacetylases and BRD4, NAD+ biosynthesis, ribosome biogenesis 
and altered HIF-1 signalling.  These findings open the path for therapeutic strategies targeting key 
molecular changes invoked prior to, and subsequently to, Httex1 aggregation.   
 
Keywords:  Protein misfolding, amyloid, neurodegenerative disease, Huntington’s Disease 
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INTRODUCTION 
Protein misfolding and aggregation into amyloids underlies many of the major human 
neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s and motor neuron 
disease (1). In these diseases, the appearance of macroscopic intracellular protein aggregates known 
as inclusions form as a hallmark of disease development.  Huntington’s disease (HD) is one of the 
classic examples of the amyloid diseases involving intracellular protein aggregating into inclusions.  
HD involves an expansion of a CAG trinucleotide repeat sequence, encoding polyglutamine (polyQ), 
within exon 1 of huntingtin (Htt) beyond the disease threshold of 35 repeats (2). The polyQ expansion 
leads to a greatly enhanced capacity of the Htt exon 1 (Httex1) domain to aggregate into amyloid 
fibrils in vitro (3) and for N-terminal fragments similar in length to Httex1 to form microscopic inclusion 
bodies in pathology (4, 5). The link to disease from polyQ-expanded Httex1 has been well 
documented.  Namely, the transgenic expression of polyQ-expanded Httex1 is sufficient to produce a 
HD-like pathology in rodent and primate models (6-8) and confers toxicity in cell culture models as 
well (9).  As such Httex1 has been used extensively to model HD biology. 
An outstanding question remains as to the role of aggregation in pathogenesis.  Evidence increasingly 
suggests that cellular malfunctioning originates prior to aggregation of Htt into the inclusion body – 
indeed formation of inclusions seems to aid survival (reviewed in (10, 11)).  Therefore, soluble polyQ-
expanded Httex1 states (including monomers and oligomers) may directly confer cellular toxicity and 
that toxicity could become nullified as the soluble states are sequestered into the visible aggregates.  
The mechanisms mediating the origins of cellular toxicity and inclusion assembly remain to be 
properly elucidated.  
Until recently, it has not been straightforward to decipher the cellular changes arising from polyQ-
expanded Httex1 as it shifts from soluble states into the inclusion body because cell populations 
contain mixtures of cells enriched with Httex1 in different aggregation states. This heterogeneity 
prevents a clean delineation of effects attributable to mutation from aggregation state.  
We previously developed a flow cytometry based method (Pulse Shape Analysis: PulSA) to separate 
cells expressing polyQ-expanded Httex1 into two major groups: those enriched with Httex1 in 
inclusions (i) and those enriched with soluble Httex1 states (predominantly monomer) (ni) (12) (Fig 
1a).  This methodology provides a unique opportunity to explicitly understand how aggregation state 
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of Httex1 (or indeed any mutant protein that forms an inclusion) relates to molecular dysfunction.  
Therefore, in this study, we sought to comprehensively determine how the transcriptome is altered by 
Httex1 aggregation in a cell culture model that is both sensitive to mutant Httex1 toxicity and which 
can be robustly controlled for co-variates such as time and expression level.  We show that Httex1 
provides the most profound changes to the transcriptome prior to aggregation and that the toxicity can 
be accounted for by a sustained shutdown of baseline CREB signalling from soluble Httex1.   
MATERIALS AND METHODS 
DNA vectors and constructs.  pT-REx vectors (Life Technologies) encoding Httex1 with 25Q or 72Q 
polyQ sequence lengths were prepared as described previously (12, 13).  pGW1-based Httex1-
mCherry constructs were prepared as described previously (14).    
Cell culture. Neuro2a cells, obtained originally from the American Type Culture Collection, were 
maintained in Optimem medium (Life Technologies) supplemented with 10% v/v FCS, 1 mM 
glutamine, 200 U/ml penicillin and 200 μg/ml streptomycin in a humidified incubator with 5% v/v 
atmospheric CO2. Neuro2a cells were transiently transfected with the vectors using Lipofectamine 
2000 reagent (Life Technologies) using the manufacturer’s recommendations.   
Collection of cells by Pulse Shape Analysis, RNA extraction and sequencing. 48 h after 
transfection, cells were fluorescence-activated cell sorted using a BD FACS ARIA III cell sorter. In 
essence, the cells were gated for live cell population by SSC and FSC gates and then the ‘ni’ and ‘i' 
gates by PuLSA as described (12). To match for expression, cells were further gated to the same 
median GFP intensity of 2,200 RFU by varying the window of expression (Fig S1).  The 25Q and 72Q 
Httex1 constructs were transfected and sorted in parallel across four days and performed as four 
matched replicates.  50,000 cells were collected for each sample (25Q-ni, 72Q-ni and 72Q-i) and 
sorted directly into TRI-reagent (Zymo Research, Irvine, CA). For imaging, a parallel sample set was 
collected and imaged as described previously by confocal microscopy (12). Total RNA was purified 
with the Direct Zol RNA extraction kit (Zymo Research, Irvine, CA) and verified for quality and yield 
(greater than 1 μg and RNA Integrity number of > 9) using the Bioanalyzer 2100 and RNA 6000 Nano 
Kit (Agilent Technologies, Santa Clara, CA). rRNA was depleted and the library prepared per the 
manufacturer’s protocols (TruSeq, Illumina) for whole transcriptome sequencing using Illumina Hi-Seq 
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2000 (Illumina, San Diego, CA, USA). FastQC report generated from the RNA Sequencing analysis 
showed good per base quality scores. 
RNA sequence processing.  50 base pair paired-end reads with an average library size of 15 million 
tags with at least one reported alignment (~90% mapping rate) was obtained. The reads were 
mapped to the reference mouse genome (GRCm38/mm10) using Tophat2 (2.0.13) (15) aligner. The 
gene level read counts were obtained (Ensembl transcripts release 78) using Rsubread - 
featureCounts (v1.4.6-p1) (16) using RStudio (Version 0.99.1246) /R (Version 3.3.1).  
Differential expression analysis of RNA sequencing data. Differential expression analysis of RNA 
sequencing data was conducted using voom transformation and limma differential expression 
analysis pipeline in R-bioconductor (Version 3.3). Genes were first filtered if they did not have at least 
1 counts per million mapped fragments, in more than three libraries. Counts were converted to log2 
counts per million, normalized using the trimmed mean of M-values normalization method (17) and 
precision weighted with the 'voom' function of the limma package (v3.24.15) (18). A linear model was 
fitted to each gene with effects for the sample types (25Q-ni, 72Q-ni and 72Q-i) as well a further fixed 
effect for the four replicate batches that the samples were PuLSA sorted across four days. Empirical 
Bayes moderated t-statistics were used to assess differences in gene expression. Statistical tests for 
differences in expression levels were evaluated by comparing between the sample groups: i.e. the 
72Q-ni vs. 25Q-ni, 72Q-ni vs 72Q-i, 72Q-i vs 25Q-ni and total 72Q (72Q-i + 72Q-ni) vs.25Q. Genes 
were adjusted for multiple testing and significant genes were designated as having a false discovery 
rate (FDR) <0.05 using decideTest function in limma. The upregulated genes were labelled 1; 
downregulated genes -1; and not differentially expressed genes 0 (Table S1c). KEGG pathway 
analysis was performed with DAVID v6.8 using a minimum gene count of 10 and a modified Fisher 
Exact P-Value of <0.01 with FDR correction (19 , 20).  
STRING analysis. The differentially expressed genes between the 72Q-ni and 25Q-ni with FDR 
corrected p-values <0.05 and fold change of >2 were used to create a protein: protein interaction 
network with the STRING v.10 algorithm (21). Data were analysed with parameters including only 
experimentally obtained data and a medium confidence interaction score of 0.40. 1st shell interactors 
of no more than 5 proteins was used.  
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Upstream regulator analysis. Upstream regulator analysis was performed on the genes differentially 
expressed between the 72Q-ni and 25Q-ni with Ingenuity Pathway Analysis (IPA) (Qiagen). IPA 
compares gene expression in a dataset with lists of genes that are known to be regulated by specific 
upstream transcriptional regulators, to infer whether a regulator is likely to be activated or inhibited. 
Since there is a considerable overlap in the lists of gene regulated by different transcriptional 
regulators, multiple points along a pathway can be suggested as key regulators, which can lead to a 
significant redundancy in the analysis. In IPA, this effect is quantified by the activation z-score 
statistics, which increases or decreases depending on the inferred activation/inhibition state of an 
upstream regulator. Significance in IPA was attributed to upstream regulators that have an overlap p-
value of < 0.01 and an activation z-score of greater than 2 or less than −2.    
Heuristic post hoc analysis of gene expression data. Gene expression data were classified into 
different transcriptional signatures using significant results (FDR<0.05) obtained by decideTest 
function in limma on different comparisons. The transcription signature groups included genes with 
the criteria as described below (in both positive and negative directions (i.e –1 or 1) for each 
signature. Progressive fold change to determine the direction of expression change across 
aggregation states was calculated using the formula (fold change 72Q-ni vs 25Q-ni) * [Absolute(fold 
change of 72Q-i vs 25Q-ni  – fold change of 72Q-ni vs 25Q-ni)]. 
Gene expression signature Decide test 
72Q-ni vs. 
25Q-ni 
Decide test 
72Q-i vs. 
25Q-ni  
Decide test 
72Q-ni vs. 
72Q-i 
Progressive 
fold change 
Transcription signature group 1 1 1 0 – 
Transcription signature group 2 0 1 1 – 
Transcription signature group 3 1 1 1 >0 
Transcription signature group 4 1 0 – <0 
For each transcription signature group 1 the genes were subdivided into upregulated and 
downregulated gene lists with regard to direction of expression in 72Q-ni vs 25Q-ni comparison.  The 
genes which did not fall into the categories mentioned above were excluded from the analysis.   
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Network Analyst – Minimal interaction networks. The gene expression signatures were mapped to 
known protein: protein interaction networks using network analyst toolkit (22, 23).  In essence, genes 
in a transcriptome signature group were mapped to a validated network of all known binary protein: 
protein interactions. The network was trimmed to contain only proteins that connect the input genes. 
The most connected genes remaining in the network that had a degree centrality of >30 formed the 
hubs. The most locally well-connected subnetworks with a statistical threshold of Wilcoxson rank-sum 
P-values <0.05) were extracted as modules. 
R6/1 mouse tissue processing, RNA extraction and microarray analysis.  R6/1 hemizygote 
males (24) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and bred with CBB6 
(CBAxC57/B6) F1 females to establish an R6/1 colony. Genotypes were determined by PCR (24) with 
genomic DNA obtained from toe clips. Wild-type (WT) and R6/1 HD male mice were collected after 
weaning at 3.5 weeks of age and transferred into standard mouse cage boxes, 10 cm × 16 cm × 31 
cm in size, in groups of 3–6. 
WT and HD mice were killed at 12 weeks of age by cervical dislocation between 9–11:30 am.  
Different experimental groups were randomly allocated into balanced batches to eliminate batch 
effects. Brains were removed, rinsed in PBS and placed on ice for no more than 5–10 minutes prior to 
dissection. Brains were bisected and striatum was dissected out. Samples were immediately frozen 
on dry ice and transferred to a –80 °C freezer for storage until required.  
Total RNA from the striatum was extracted using RNeasy Mini kits (Qiagen). On-column DNase 
clean-up was performed on all samples using RNase-Free DNase set (Qiagen). The concentration 
and integrity of the extracted total RNA present in the final eluates were determined using an Agilent 
Bioanalyser 2100. All the samples had a RIN of greater than 9.3. GeneChip Mouse Exon 1.0ST 
arrays (Affymetrix, Santa Clara, CA, USA) were used, with hybridization and scanning conducted by 
the Australian Genomics Research Facility (Parkville, Australia) per standard Affymetrix protocols, 
with appropriate quality control (QC).  
Microarray data was analysed using the limma package (v3.24.15) in R-bioconductor (Version 3.3). 
The arrray data was preprocessed and quality control was done using the oligo package . The 
normalization was done at the probe level using Robust Multi-Array Average method  in oligo (25). 
The probeset annotation was done using the Affymetrix mogene10 annotation data package (version 
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8.4.0) (26). The statistical testing of changes in gene expression of transgenic R6/1 HD mice was 
compared to wild-type littermates using a linear model in limma (Supplementary Table S2a). The 
pathways were obtained using IPA core analysis with gene changes attributed specifically to neuronal 
tissue in IPA knowledge base.  
Human caudate gene analysis. Previously published raw microarray data (27) was retrieved from 
the EBI Array Express database (28) (http://www.ebi.ac.uk/arrayexpress) under accession number E-
AFMX-6. The raw data was processed and normalized using the bioconductor affy package (v1.52.0) 
(29) with the Robust Multi-Array Average method (30) and differential expression was tested in limma 
(v3.24.15) in R-bioconductor (Version 3.3). Gene-set enrichment analyses were conducted using the 
caudate genes as the reference set and our cell-based RNA-seq data as the gene set with the Roast 
function in limma (31). 
Longitudinal live cell imaging. The cells were plated at a density of 1u105 cells/ well in a 24 well 
plate.  After 24 h, cells were co-transfected with 72Q-Httex1-mCherry, 25Q-Httex1-mCherry or 
mCherry alone and GFP using Lipofectamine 3000 reagent (Life Technologies). Media was refreshed 
6 h after transfection.  The GFP was used as a cellular tracer of death and proxy for Httex1 
expression level. After 24 h cells were imaged using a JuLI stage live cell imaging system with 
fluorescent images acquired at 15 min intervals for 96 h (Nanoentek, Seoul, South Korea).  Cells were 
tracked for visible aggregate formation and the time point of death (by loss of GFP fluorescence) with 
image processing tool Fiji (Version 2.0.0-rc-44) (32).  Survival curves were analyzed using Prism 
software.  Cells that drifted from focus were censored in the analysis.  Expression level was 
calculated by measuring mean GFP levels in an ROI within the cytosol. The cells included for analysis 
had a mean fluorescence ± 2 standard deviation of the sample with the lowest variance. P-values 
were determined using log-rank (Mantel Cox) test. For drug treatments, forskolin (Cayman Chemical) 
was added after transfection to a concentration of 0.5 μM, which corresponds to the EC50 dosage.  
CREB inhibitors SGC-CBP30 (20 nM) and I-CBP112 (150 nM) were added after transfection (Sigma-
Aldrich).  Both drugs were added at 6 h post transfection during media refreshment.   
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RESULTS & DISCUSSION 
Cell populations expressing matched Httex1 levels divided into those with inclusions versus 
those without 
Our model system was a mouse neuroblastoma cell line (Neuro2a), which is a widely used model for 
studying Htt-induced pathogenic mechanisms.  These cells were selectively vulnerable to toxicity of 
polyQ-expanded Httex1 (72Q) over the wild-type polyQ length (25Q) (both as fusions to mEmerald 
fluorescent protein (33)) (Fig 1b).  In accord with prior observations, the formation of inclusions 
repressed the rate of death relative to cells retaining exclusively diffuse mutant Httex1 (9).   
In transfected cell populations the levels of Httex1 and aggregation rates are heterogeneous (12).  To 
remove this heterogeneity and enrich for cells with aggregates versus those without we used PulSA 
(12). PulSA enabled the separation of cells with inclusions (i) from those without (ni) in non-expanded, 
wild-type (25Q) and expanded, mutant (72Q) forms of Httex1, using a gating strategy that matched 
expression levels across our three groups (25Q-ni, 72Q-ni and 72Q-i) (Fig 1c; Fig S1).  This strategy 
captured a snapshot of cells representing the extreme ends of the spectrum of aggregation states, 
and which enriches cell groups with greater than 90-95% fidelity (34, 35).   
The largest changes in the transcriptome are stimulated by soluble mutant Httex1 
Next-generation RNA sequencing (RNAseq) yielded 12,876 high abundance genes on four biological 
matched replicates. To first test whether our dataset yielded results in accord with previous HD 
datasets, we tested for differential expression between the disease like 72Q samples (72Q-ni+ 72Q-i) 
and 25Q-ni as control. Comparing these two groups with the previously described human caudate 
microarray data from HD brain (versus non-HD controls) (27) we observed 1,109 differentially 
expressed genes in common to both. The upregulated genes detected in mouse were found to be 
significantly enriched for upregulated expression in the human samples. That is, we took the 
significantly upregulated genes detected in our mouse study (n=428 genes) and used this as a gene 
set for testing with Roast (31) in the human study (FDR =0.01). These results are indicative of a 
general consistency in upregulated genes between our cell model and human caudate samples. 
As an additional test, we found that our 72Q samples treated as one group (72Q-ni+ 72Q-i) versus the 
25Q-ni group yielded several HD-relevant KEGG pathways (Supplementary Table S1a). This included 
DNA repair (36), p53 signalling (37) and RNA transport (38).  
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To understand how aggregation state affected transcription, we measured the differential expression 
patterns for all pair-wise comparisons between the three sample Httex1 groups: 25Q-ni, 72Q-ni and 
72Q-i.  The Httex1 72Q-ni versus the 25Q-ni comparison yielded changes to how soluble mutant 
Httex1 affected expression while the 72Q-i versus the 72Q-ni comparison assessed more specifically 
how aggregation of mutant Httex1 into inclusions affected expression (Fig 2). These analyses 
indicated that the largest and most significant changes occurred from mutant Httex1 when it was 
soluble prior to inclusion assembly.  Furthermore, most of the changes were sustained in cells with 
inclusions (Fig 2 and Table S1c).   
Inactivated CREB-CREM signalling is the most profound impact arising from soluble Httex1 
Next, we probed the dataset for clues as to how the transcriptional changes triggered by the soluble 
mutant Httex1 relate to mechanism of toxicity.  First, we performed a STRING network analysis (21) 
(on human protein counterparts) of the genes most altered in expression to see if they correlated with 
validated protein-protein interactions.  Of the 9 genes upregulated more than 2-fold in the 72Q-ni 
condition (versus 25Q-ni), 3 formed part of the CREB signalling network (NCOA3, MDM4 and 
RUNX2) (Fig 3a). CREB is a key transcription factor that has been previously implicated as defective 
in HD (39, 40, 41 , 42-45). Furthermore, CREB signalling has been suggested to be mediated by 
deactivation of CREB binding protein (CREBBP) activity through abnormal interactions with soluble 
Httex1 (44, 46-48).  There was no significant change in CREBBP or CREB transcript levels.   
We next sought to measure the extent to which the changes in transcriptome can be explained by 
alteration of CREB activity.  To do this we performed an unbiased Upstream Regulator Analysis using 
Ingenuity Pathway Analysis (IPA). The principle behind this analysis is to search for changes in 
transcription factor activity that accounts for the changes in downstream gene expression as 
represented by our dataset.  16 transcription factors were identified that are known to regulate the 
genes in our dataset.  Critically, only 2 of these transcription factors, CREB and the closely 
functionally related CREM, could explain the altered expression patterns of our data with high 
confidence by their inactivation (Fig 3b, Table S1b).  These data collectively suggest that CREB 
signalling defects are among the most pervasive of the changes in the transcriptome (including before 
and after aggregation) and that these effects are attributable to mutant Httex1 before aggregation.  
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To test for the in vivo relevance of these findings, we also examined the mRNA of R6/1 Httex1 
transgenic mouse (24) striatum tissue at a time point prior to motor onset (12 weeks of age) by 
microarray analysis.  Analysis of the gene expression differences in the R6/1 genotype (n=3) versus 
non-transgenic littermates (n=4) indicated CREB signalling (and related cAMP signalling) were in the 
top 5 pathways negatively impacted in an IPA canonical pathway analysis (Table S2a,b).   
Dampened CREB signalling explains the molecular basis of toxicity 
To further examine the importance of CREB inactivation in toxicity we performed survival curve 
analyses focusing on manipulating CREB signalling (Fig 3c).  Prior studies have found that deletion of 
CREB-CREM expression in postnatal forebrain results in extensive neurodegeneration reminiscent of 
HD pathology (42). Inhibition of CREB signalling with inhibitors SGC-CBP30 and I-CBP112, which 
target CREBBP and EP300 bromodomains with high specificity (49, 50), in our Neuro2a culture 
system led to a high death rate indicating that baseline CREB signalling is critical for cell survival (Fig 
3d).  Cells expressing mutant Httex1 were negatively impacted by inhibition of CREB signalling, as 
anticipated (Fig 3c). However, activation of CREB signalling with forskolin, which triggers downstream 
phosphorylation and activation of CREB (51), significantly rescued the toxicity caused by mutant 
Httex1 and had otherwise no effect on baseline survival rates in cells with the wild-type Httex1. 
Collectively, these results suggested that toxicity of soluble mutant Httex1 manifests predominately 
through impairment of baseline CREB signalling and that this be remedied by triggering the CREB 
signalling.  
Additional novel pathways unearthed as transcriptional signatures for Httex1 aggregation 
We next focused on extracting other patterns in the dataset using a transcriptional signature approach 
as shown in Fig 4a using a post hoc heuristic analysis.  These signatures can be used to make 
predictions about how cells respond to Httex1 aggregation state in both pathogenic and adaptive 
manners.  This analysis yielded hundreds of genes in each transcriptional signature group.  Features 
were extracted from this data using the Network analyst software (22), which links together genes 
based on their known protein-protein interactions. The most connected genes in the networks (set 
with a minimum threshold of 30 interactions) were identified as hub genes of interest (Table S3). 
Functional subnetworks (modules) that relate more discretely to biological functions were also 
identified using a Walktrap algorithm in Network analyst (Fig 4b).  The final list (as discussed below) 
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of modules and hub genes has an extensive overlap with established HD mechanisms.  There was 
also a strong overlay with CREB signalling, which suggests these modules are affected directly by the 
dampened CREB signalling response or are adaptive responses to counteract CREB signalling 
defects.   
We explain the key details of these modules below and provide a discussion of how they may connect 
to CREB signalling and HD biology (and expanded on in Supplementary Note 1).  This discussion 
outlines what we see are the key features of the data set and point to connections with established 
links to Huntington’s disease biology and other features of potential interest. 
Transcriptional signature 1:  This signature describes the changes invoked by soluble mutant Httex1 
and which have no further change when inclusions form. One explanation for this signature is to 
describe changes occurring as a result of toxic responses.  This may apply for the HDAC5 and BRD4 
modules, for which HDAC5 and BRD4 genes are chromatin modifiers that have been shown to 
influence CREB signalling, which are consistent with the broader changes seen in CREB signalling 
(52-54). HDAC proteins have also been previously linked to underlying HD pathogenesis (see 
Supplementary Note 1 for more discussion).  
Other modules are more likely to reflect responses to counter the toxic effects of Httex1. Such 
upregulated modules (named after the key genes in them) included HDAC5, BRD4, NAMPT, 
ribosome-associated proteins and GABARAP. GABARAP, ELAVL1 and SQSTM1 genes have roles in 
regulating macroautophagy and proteasomal-mediated degradation and have been shown to be 
involved in HD pathology (see Supplementary Note 1 for more discussion). Their upregulation thus 
may indicate attempted increased clearance mechanisms to cope with the toxic Httex1 response.  
However, for GABARAP the changes may also reflect a block in autophagy (discussed in more detail 
in Supplementary Note 1). NAMPT gene encodes the rate-limiting enzyme in NAD production, which 
is an essential cellular metabolite involved in energy production, redox homeostasis, Ca2+ signalling 
and post-translational modifications.  Prior work has shown that misfolded prion protein can reduce 
oxidised NAD (NAD+) levels (55), hence the upregulation of NAD+ may reflect a compensation 
response. Increased SUMOylation of Htt has been suggested to facilitate disaggregation of Htt, 
thereby releasing the soluble mutant Htt monomers and increasing neurotoxicity (56).  Hence 
reduction of SUMO pathways may indicate an adaptive response to aid sequestration of the soluble 
Httex1 states. 
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Transcriptional signature 2:  This signature describes the transcriptional changes that are only altered 
when inclusions form.  One possibility to explain this signature are the genes that change expression 
upon adaptation responses as inclusions form on the basis of prior work suggesting inclusions are 
actively formed to sequester toxic soluble protein states (9, 57, 58). Up-regulated modules include 
RELA, which is a subnetwork within the NF-κB signalling pathway that has been implicated in HD (59) 
and ribosomal associated protein module, which has functions in regulating ribosome biogenesis (60). 
As such their upregulation may be part of mechanisms to globally regulate protein translation.  Of 
note to the broader connection to CREB signalling alterations, CREB signalling regulates ribosomal 
protein production and aberrant production has been linked to ribosomal stress and apoptosis (61). 
Five modules were downregulated in this group. Within these modules, the PAXIP1 gene is involved 
in DNA repair and the CDK1 gene is involved in cell cycle re-entry.  Both have been previously linked 
to HD pathology and in toxicity (explained further in Supplementary Note 1).  A notable downregulated 
module was EP300.  The EP300 gene encodes a co-activator of CREB, which suggests this response 
is influenced by the broader deregulation of CREB signalling.  Also downregulated is the UBC 
module.  UBC encodes ubiquitin, which is involved in ubiquitin-proteasome mediated protein 
degradation.  This response is likely part of broader adaptation changes to protein folding stress 
(more details are explained in Supplementary Note 1).   
Transcriptional signature 3:  This signature describes a change of transcript levels triggered by 
soluble Httex1 and extended further when inclusions form.  This signature may reflect a sustained or 
delayed toxicity response; or alternatively a delayed or amplifying adaptive response as aggregation 
proceeds. Upregulated modules included NF-kB pathway (more generally than the RELA subset).  
This may reflect a compensation response since increased NF-kB signalling aids cell survival (62).  
Down-regulated modules included KIAA0101, HNF4A and MYC. KIAA0101 gene is involved in 
oxidative stress mediated DNA repair (63), HNF4A gene is involved in the metabolic regulation of 
glucose and lipids has been shown to be impaired in HD (64, 65) and MYC gene is a master regulator 
of protein transcription (and indirectly translation) and is influenced by CREB signalling (66). Thus, the 
changes in MYC likely reflect an amplifying adaptive response to bypass defects in CREB signalling 
as well as aiding cell survival by reducing translation under stressed conditions. 
Transcriptional signature 4:  This signature describes transcript changes invoked by soluble 72Q 
Httex1 that then return to control levels when inclusions form.  This signature could reflect genes that 
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are specifically rebalanced by aggregation in adaptive responses from inclusion formation.  The 
upregulated modules included STAT3, of which the STAT3 gene works in concert with NF-κB to 
regulate cell survival (67) and VHL, which directs Hypoxia-inducible factor-1 (HIF-1) for degradation 
via the ubiquitin-proteasome system and suppresses apoptosis. The sole down-regulated module 
included HSP90AA. HSP90 and related chaperones link closely to systems regulating protein folding, 
degradation and potentially disaggregation (68). 
Conclusions 
In conclusion, our study has enabled the first comprehensive view of how aggregation state of Httex1 
influences the transcriptome in HD.  Most noteworthy was the finding that soluble Httex1 propagates 
the most substantial changes in the transcriptome by blocking CREB signalling, which supports an 
extensive body of work indicating CREB signalling defects as central to HD pathomechanisms.  
Importantly, our study is the first to our knowledge that has been able to identify this defect as 
specifically attributed to the soluble mutant Httex1 and in context of the system-wide transcriptional 
changes.  Indeed, the blockage of CREB signalling seemingly accounted for the majority of the 
toxicity caused by Httex1.  As such, our data reaffirms CREB signalling as a highly attractive 
therapeutic target in Huntington’s disease.  This conclusion is supported findings that an 
enhancement of CREB levels via Sirt1 overexpression in the R6/2 HD mouse model can improve 
survival time (69).  In contrast, the formation of inclusions offers (by comparison) trivial changes in the 
magnitude of transcriptional changes.  Moreover, of the changes observed, the signatures point to 
those involved in adapting to defects in CREB signalling such as the rewiring of CREB-related signally 
networks to compensate for CREB deficiency.  In addition, other changes associated with protein 
homeostasis responses were also documented in these signatures.   
Another feature of our dataset was the pronounced enrichment of genes encoding polyQ. Five of the 
9 genes upregulated more than 2-fold by the soluble polyQ-expanded Httex1 contained endogenous 
polyQ sequences suggesting that polyQ-expanded Htt may more broadly deactivate by soluble co-
aggregation these proteins leading to their compensatory upregulation (Fig 2).  Three of the 
upregulated polyQ-encoding genes are involved in CREB signalling, which may explain why CREB 
signalling appears to be the most profoundly affected pathway (Fig 3a).     
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Our new roadmaps of the transcriptional changes associated with Htt aggregation states offer a 
powerful resource to understanding how Httex1, notably the soluble forms, propagates toxicity as well 
as in yielding CREB signalling as a therapeutic target for further investigation. 
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LEGENDS TO FIGURES 
Fig 1: Strategy to separate cells into populations enriched with polyQ-expanded Httex1 in 
distinct aggregation states.  a) Pulse Shape Analysis (PulSA) by flow cytometry can separate cell 
populations heterogeneous in aggregation state.  b) Neuro2a cells that form inclusions live longer 
than those that do not.  Shown are Kaplan-Meier survival curves tracked by longitudinal imaging of 
Httex1-Emerald fusions from 20 h after transfection. P-values refer to log-rank test (Mantel Cox) on 
survival curves. c) Flow cytograms showing the PulSA gating strategy to sort the mixed cell 
populations for analysis by whole transcriptome analysis.  Shown are gates for i and ni and for 
matched expression (red; Further details in Fig S1).   The images show representative cells collected 
by sorting flow cytometry and imaged for GFP fluorescence by confocal microscopy.  Scale bar, 20 
μm. 
Fig 2: Volcano plots of gene expression changes attributable to aggregation states of Httex1.  
Shown are comparisons between the three treatment groups: cells lacking visible aggregates but 
differing in polyQ length (25Q-ni and 72Q-ni cells) and cells with expanded polyQ length that differ in 
aggregation state (72Q-i).  Genes with a FDR less than P=0.05 are shown in red.  Genes with greater 
than 2-fold change are shown in blue.  Genes encoding proteins with an intrinsic native polyQ 
sequence have orange labels.   
Fig 3: CREB signaling is dampened by soluble mutant Httex1 and explains the major source of 
toxicity to Neuro2a cells.  a) A protein-protein interacting network of the genes enriched more than 
2-fold in cells enriched with soluble mutant Httex1.  Shown are STRING (v10) validated protein-
protein interactions of genes corresponding to those enriched in the dataset.  The network was built to 
include first shell interactors (i.e. interacting proteins corresponding to genes not enriched in the 
dataset).  b) Upregulator analysis (Ingenuity) to explain how changes in differential expression 
patterns of our dataset relate to changed protein activity of transcription factors. The inner circle 
shows transcription factors that control genes seen differentially expressed in the dataset.  The outer 
ring shows the key genes in our dataset that are targets of the transcription factors and their patterns 
of expression.  c) Schematic of CREB signaling activity and role of activator forskolin.  d) Effect of 
upregulating (with forskolin) or suppressing (with inhibitors CREB signaling SGC-CBP30 and I-
CBP112) on survival curves. P-values corresponds to log-rank (Mantel Cox) tests. 
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Fig.4:  Transcriptional signatures for Httex1 aggregation state. a) Shown is our model for how 
transcriptome data can be mapped to the changes attributable to mutation, and then aggregation into 
inclusions.  Data are filtered into transcriptional signatures as represented by the bar graphs, based 
on changes with FDR <0.05 (n=4).  b) Shown are functional modules (with Wilcoxson rank-sum P-
values <0.05), and their designated names, extracted from protein: protein interaction networks 
corresponding to all the genes in each transcriptional signature using Network Analyst Walktrap 
software. These modules can be upregulated or downregulated in the transcriptional signature (and 
the direction is shown). Each module shows the genes (points) and their connections.  The most 
connected genes in the modules are labelled.  
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Fig. 2 
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Fig. 3 
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Highlights 
x Transcriptional changes due to aggregation of mutant Httex1 are described 
x The largest changes in the transcriptome are stimulated by soluble mutant 
Httex1 
x Inactivated CREB signalling is the most profound impact arising from soluble 
Httex1 
x Dampened CREB signalling explains the molecular basis of toxicity 
x Additional pathways unearthed as transcriptional signatures for Httex1 
aggregation 
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